drugset / Trial / NCT00956306

A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function

NCT00956306

Phase 1 Completed 18 enrolled Dong-A Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

This study is designed to assess the effect of hepatic impairment on the pharmacokinetics, safety and tolerability of udenafil in subjects with hepatic impairment compared to healthy subjects.

Timeline

Start
2007-11
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Udenafil Small molecule 100 mg Oral

Indications

No indication recorded.